Ovarian Cancer
Conditions
Keywords
PARP inhibitor, Fluzoparib, Bevacizumab, Platinum - sensitive recurrent EOC
Brief summary
There are more and more PARPi(PARP inhibitors) resistance for ovarian cancer patients after previous use of PARP inhibitors. Basic studies have found that there is synergistic effect of bevacizumab combined with PARPi. Therefore we designed the study to include 42 ovarian cancer patients who had PARPi for at least half a year and then relapsed (platinum-sensitive, previously 1-3 lines of chemotherapy). After getting complete remission or partial remission with chemotherapy containing platinum and bevacizumab, fluzopanib and bevacizumab were used for maintenance treatment. The progression-free survival, ORR, DCR, DoR, and safety were evaluated based on RECIST V1.1.
Detailed description
Genetic testing of tissue samples before and after the maintenance therapy were also used to further explore the pattern of gene mutations and the subgroups who may benefit.
Interventions
DRUGfluzopanib and bevacizumab
fluzopanib and bevacizumab were used for maintenance treatment
Sponsors
Chongqing University Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Ovarian cancer patients with histopathological type: low/high grade serous carcinoma, endometrioid carcinoma,had received platinum-based regimens for at least 1-3 lines after primary cytoreductive surgery. 2. The patient had at least one measurable lesion according to the RECIST V1.1 criteria. 3. The time from the last cycle of chemotherapy to relapse/progression should be more than 6 months. 4. ECOG score 0\ 1,age 18\ 75 years old 5. The serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial 6. CBC Hb≥90g/L, ANC≥1.5×109/L, PLT≥100×109/L, 7. Serum ALT≤3×UL, AST≤3×ULN#Serum creatinine≤1.5×ULN#
Exclusion criteria
1. Had used bevacizumab within 6 months of enrollment 2. Has combined with other malignant tumor which diagnosed within 5 years and/or needed to be treated. The patients had untreated CNS metastases. 3. The patient had Recent intestinal obstruction, gastrointestinal perforation within 3 months, uncontrolled high blood pressure after medication (Systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg), Moderate to severe cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), moderate to severe deep vein thrombosis and moderate to severe pulmonary embolism occurred within 6 months before enrollment. Patient with coagulation dysfunction. 4. Myocardial infarction, severe arrhythmia and NYHA (New York heart association)≥2 for congestive heart failure 5. Activity or uncontrol severe infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 5 years | progression-free survival was the maintenance time to progression or recurrence since the last platinum therapy based on RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | 5 years | Overall survival |
| ORR | 5 years | Objective Response Rate |
| DCR | 5 years | Disease control rate |
| DoR | 5 years | Duration of remission |
Other
| Measure | Time frame | Description |
|---|---|---|
| saftey | 5 years | The severity of adverse events was determined according to CTCAE V5.0 criteria. During the trial, the adverse event record form should be truthfully filled in, including the occurrence time, severity, correlation with study treatment, duration, measures taken and outcome of the adverse event |
Countries
China
Contacts
Primary ContactZou Dongling, PH.D.
Backup ContactLin Zhong, M.D.
Outcome results
None listed